Loading
A phase 2 trial of Cisplatin, Tislelizumab and Capecitabine in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] is a phase 2 interventional study registered as NCT07331155 by Nanjing Leads Biolabs Co.,Ltd, with 110 participants planned, started 2026-02-26 and due to reach its primary completion in 2028-12-26. Interventions recorded: LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection, Tislelizumab Injection, 5-Fluorouracil injection and Capecitabine tablets.
Shares Nanjing Leads Biolabs, Tislelizumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.